Pharming Group Securities Investigation

Levi & Korsinsky, a securities litigation firm, has commenced an investigation into Pharming Group N.V. (NASDAQ: PHAR) concerning potential violations of federal securities laws. The investigation follows a 22% drop in Pharming's stock on July 30, 2026, after the company reported second-quarter revenue of $90.2 million, down 3% year-over-year, and cut its full-year 2026 revenue guidance to $375-$395 million from $405-$425 million. The revenue shortfall was primarily driven by a 10% year-over-year decline in sales of RUCONEST, the company's legacy hereditary angioedema therapy, which fell to $72.3 million. In contrast, Joenja revenue rose 40% to $17.9 million. Diluted EPS came in at $0.002 versus $0.006 in the prior-year period. The investigation focuses on whether Pharming and certain officers adequately disclosed competitive and demand pressures affecting RUCONEST prior to the July 30 announcement. CEO Fabrice Chouraqui had previously stated on a November 2025 earnings call that the company did not see RUCONEST competing head-to-head with sebetralstat, a competing therapy. The reduced FY 2026 outlook sits roughly $30 million below the prior midpoint and below analyst consensus of approximately $419 million. Levi & Korsinsky is soliciting affected shareholders to participate in the investigation.